Rapid Medical announced that it received FDA 510(k) clearance for its Tigertriever 13 device for treating large vessel occlusions.
Yokneam, Israel-based Rapid Medical designed Tigertriever 13 to remove thrombus from delicate brain blood vessels during an ischemic stroke.
Rapid Medical said in a news release that Tigertriever 13 is the smallest revascularization device in the world to date, adjusting to the vasculature and clot through a more atraumatic approach than existing devices.
“Thousands of procedures have already been performed with Tigertriever 13 worldwide,” Rapid Medical President, Americas James Romero said in the release. “Now U.S. physicians finally have access to Tigertriever 13’s unique capabilities to further benefit patients suffering from ischemic stroke.”
The company said Tigertriever has adjustability capabilities that existing stent retrievers lack, with three-dimensional braiding borrowed from recent advances in aerosp…